Tenderwize
Back to tender search

Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD)

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 376 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

The notice explicitly states this is not a public procurement subject to competition law; legal recourse is via social...

Structured data indicates EU-funded (isEuFunded: true), but XML notice explicitly says no-eu-funds. This may affect rep...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply of Eculizumab (excluding indications gMG and NMOSD) under discount agreements with participating health insurance funds.
  • Agreement is open to all eligible pharmaceutical entrepreneurs; no exclusivity granted.
Show full summary

The tender is an Open House procedure for the conclusion of discount agreements (Rabattverträge) under § 130a Abs. 8 SGB V for the active substance Eculizumab (excluding the indications gMG and NMOSD). It is not a public procurement subject to competition law but a voluntary framework. All eligible pharmaceutical entrepreneurs can join at any time during the contract term (max 17 months from 1 April 2026 to 31 August 2027). No estimated value is provided. The procedure is open, with no negotiation on terms. Submission is via email or post, not through the e-procurement portal. The notice is in German, performance in Germany.

Risks

The notice explicitly states this is not a public procurement subject to competition law; legal recourse is via social...

Structured data indicates EU-funded (isEuFunded: true), but XML notice explicitly says no-eu-funds. This may affect rep...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG for the offered medicinal products.
  • Must hold a valid marketing authorization for the medicinal product(s) or be otherwise entitled to place them on the market.

Administrative

  • Must submit a self-declaration regarding authorization and reliability (Anlage 4).

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD)

Conclusion of discount agreements for Eculizumab (excluding gMG and NMOSD) under an Open House procedure. All eligible pharmaceutical entrepreneurs can join at any time during the contract term.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Mar 2026 - Aug 2027

Category

Pharmaceutical products

Deadline

Deadline Aug 30, 2027

Procurement Details

Publication date
24 Feb 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
132076-2026

Documents (1)

Similar tenders